This is a complete emotional reaction - unless you can clearly define and specify the difference in quality and cost, and what IP was brought and is being “cloned”.

Folks - there is the science of Leronlimab and there is the buisness of Cytodyn. While those two are connected, don’t confuse the two. Let Nader and team do their jobs. The reality is no one on this board knows why that buisness decision was made - it doesn’t change the science of Leronlimab, it doesn’t change the trial outcomes, it doesn’t change the uplisting, —- accept it and move on.